



ASSOCIATION FOR MOLECULAR PATHOLOGY
Education. Innovation & Improved Patient Care. Advocacy.
6120 Executive Boulevard, Suite 700, Rockville, Maryland, 20852
Tel: 301-634-7987 | Fax: 301-634-7995 | amp@amp.org | www.amp.org

MEDIA ALERT

Association for Molecular Pathology to Bring Clinical Laboratory Leaders to Capitol Hill to Advocate for RESULTS Act

Members to call for passage of bipartisan legislation to improve Medicare reimbursement rate-setting for critical laboratory services

ROCKVILLE, Md. – May 11, 2026 – The [Association for Molecular Pathology](http://www.amp.org) (AMP), the premier global molecular diagnostic professional society, will participate in a Capitol Hill Day on May 13, bringing clinical laboratory leaders from across the country to Washington to meet with lawmakers and discuss policies affecting molecular diagnostics, laboratory medicine and patient access to testing.

AMP leaders will meet with more than 30 congressional offices to call for swift passage of the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act, known as the RESULTS Act ([H.R. 5269/S. 2761](https://www.congress.gov/bills/116/5269)). The professional society supports the bipartisan legislation because it would improve the Medicare payment system used to establish Clinical Laboratory Fee Schedule reimbursement rates, creating a more sustainable and transparent framework for laboratories while helping protect patient access to essential testing services.

Over the past 12 years, AMP has expressed concerns that Medicare payment rates under the Protecting Access to Medicare Act (PAMA) do not accurately reflect real-world testing costs nationwide because they are based on flawed and limited data that fail to account for the resources needed at various kinds of laboratories. According to AMP, the current PAMA methodology has led to significant and unintended Medicare payment reductions for many laboratory services.

The RESULTS Act would address these concerns by providing CMS with access to more representative private-payer data through a claims database for widely available laboratory tests, extending the interval between data-collection periods, mitigating the impact of year-to-year payment reductions and more. AMP believes the new policy would strengthen data quality, reduce administrative burden and improve payment accuracy and stability across the clinical laboratory sector.

WHAT: AMP Capitol Hill Day

WHO: AMP leadership and clinical laboratory professionals from across the United States

WHEN: Wednesday, May 13, 2026

WHERE: U.S. Capitol, Washington, D.C.

MEDIA OPPORTUNITIES: AMP leaders can be available for interviews, background conversations and photos throughout the day

AMP President Aaron D. Bossler, M.D., Ph.D., is the vice chair of molecular pathology at the H. Lee Moffitt Cancer Center & Research Institute. “The current Medicare payment system for laboratory services requires meaningful reform to better reflect today’s healthcare environment and to ensure patients continue to have access to essential diagnostic testing,” said Bossler. “AMP urges Congress to pass the bipartisan RESULTS Act to strengthen the long-term sustainability of clinical laboratories serving communities nationwide.”

About AMP

The Association for Molecular Pathology was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP’s more than 3,100 members practice various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions and oncology. Our members are pathologists, clinical laboratory directors, basic and translational scientists, technologists and trainees who practice in a variety of settings, including academic and community medical centers, government and industry. Through the efforts of its board of directors, committees, working groups and members, AMP is the primary resource for expertise, education and collaboration in one of the fastest-growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high-quality, appropriate testing. For more information, visit www.amp.org and follow AMP on X: [@AMPath](https://twitter.com/AMPath).

MEDIA CONTACT:

Andrew Noble
anoble@amp.org
415-722-2129
